Immunovant Inc annual earnings per share (EPS) for fiscal TTM was $-2.81, a decrease of 1.4% from $-2.77 in fiscal 2026. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-2.81 | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | $-1.54 | $-0.00 | — | $-13.67 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-0.75 | $-0.73 | $-0.61 | $-0.73 | $-0.71 | $-0.70 | $-0.76 | $-0.74 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IMVT metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding
All IMVT financial statements → Interactive IMVT charts →
About TickerBase · Data methodology & sources · Privacy · Terms